Background: We evaluated the incidence of hypersensitivity or anaphylaxis after repeated single-dose sugammadex administration in non-anaesthetised adults. Methods: In this multicentre, double-blind study (NCT02028065), healthy volunteer subjects were randomised (2:2:1 ratio) to one of three groups to receive three repeated intravenous injections of sugammadex 4 or 16 mg kg À1 , or placebo,
The incidence and severity of hypersensitivity in response to sugammadex are not known. Healthy volunteers received repeated injections of either sugammadex 4 or 16 mg kg À1 , or placebo, separated by a~5 week interval, and the presence or absence of hypersensitivity was assessed. Hypersensitivity in response to sugammadex administration can occur in healthy subjects without a history of previous sugammadex exposure.
Sugammadex, a cyclodextrin derivative, provides rapid reversal of moderate or deep rocuronium-or vecuronium-induced neuromuscular block at doses of 2 and 4 mg kg À1 , respectively.
1e6 At a dose of 16 mg kg
À1
, sugammadex is also effective for the reversal of blockade 3 min after an intubating dose of rocuronium 1.2 mg kg À1 when there is an immediate need to reverse the neuromuscular block. 7 Sugammadex received approval from the US Food and Drug Administration in December 2015, and is currently marketed for use in >70 countries worldwide. Sugammadex is generally well tolerated, but a low incidence of hypersensitivity has been observed in clinical studies 8, 9 ; hypersensitivity and anaphylaxis events have also been reported post-marketing. 10e17 Therefore, a previous repeatdose placebo-controlled study was conducted in 448 healthy, non-anaesthetised subjects (ClinicalTrials.gov identifier NCT00988065; sponsor protocol number P06042). Hypersensitivity was adjudicated in seven (4.7%), one (0.7%), and zero (0.0%) subjects receiving sugammadex 16 and 4 mg kg
, and placebo, respectively. There was one case of anaphylaxis in the sugammadex 16 mg kg À1 treatment group adjudicated using the Sampson criteria. 18 However, protocol deviations were identified after study completion, some of which may have compromised the study blinding, which could introduce bias in the assessment of incidence of hypersensitivity and anaphylaxis. Therefore, the current study was conducted to characterise further the potential risk of hypersensitivity and anaphylaxis after initial and repeat exposures to sugammadex in healthy, non-anaesthetised adult subjects. The exploratory objectives included measurement of concentrations of antisugammadex-specific immunoglobulin (Ig) G and IgE antibodies, and mast-cell tryptase concentrations.
Methods

Study design and subjects
This randomised, double-blind placebo-controlled study (protocol MK-8616-101; NCT02028065) was conducted at four study centres in the USA and two in Belgium. Subjects aged 18e55 yr, with BMI !19 and 32 kg m À2 , and judged to be in good health, based on medical history, physical examination, vital-sign measurements, ECG, and capillary-refill-time measurements, were enrolled. The exclusion criteria are summarised in Supplementary methods. The study was conducted in accordance with principles of Good Clinical Practice, and was approved by the appropriate institutional review boards and regulatory agencies. Written informed consent was obtained from all participating subjects. The subjects were randomised in a 2:2:1 ratio, using a computer-generated allocation schedule, to receive three repeat i.v. bolus injections of sugammadex 4 mg kg
À1
, sugammadex 16 mg kg
, or placebo (normal saline), with an approximate 5 week period between each dose, to allow potential sensitisation to develop. Each i.v. bolus injection was administered in approximately 10 s to match closely clinical practice.
Hypersensitivity assessment
Hypersensitivity was defined as objectively reproducible symptoms and signs of allergic disease initiated by exposure to a defined stimulus at a dose tolerated by non-hypersensitive persons.
Targeted hypersensitivity assessments were performed at 0.5, 4, and 24 h after dosing. The assessment included elicitation of symptoms and examination of the subject, covering neurological, pulmonary, cardiovascular, gastrointestinal, and dermatological domains (Supplementary methods). The assessment was performed by a blinded investigator not involved in the preparation or administration of the study drug. To ensure subject safety, a physician with expertise in airway management was available to treat the subject if severe hypersensitivity symptoms were to occur during the first 4 h after dosing. Hypersensitivity signs or symptoms in the first 24 h after dosing were referred to a blinded independent Clinical Adjudication Committee for evaluation by allergy and anaesthesia experts ( Table 1) .
The Sampson criteria are generally accepted as the best definition of anaphylaxis, and were developed via a large collaborative group, including the National Institute of Allergy and Infectious Diseases. 18 Sampson Criterion 1 is defined as acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g. generalised hives, pruritus or flushing, and swollen lipsetongueeuvula), and at least one of the following: (i) respiratory compromise [e.g. dyspnoea, wheezing/bronchospasm, stridor, reduced peak expiratory flow (PEF), and hypoxaemia], and (ii) reduced BP or associated symptoms of end-organ dysfunction [e.g. hypotonia (collapse), syncope, and incontinence]. Criterion 1 is limited to reactions, in which the affected subject is not known to be allergic to the potential allergen. Cases of potential hypersensitivity referred to the Clinical Adjudication Committee were classified as anaphylaxis if Sampson Criterion 1 was met. Subjects with potential hypersensitivity remained confined to the study centre for monitoring until the investigator considered it safe for them to leave. Resuscitative equipment and rescue treatments were available at each study centre. Subjects with hypersensitivity-related adverse events of severe intensity or requiring treatment, those with serious adverse events (related or not to hypersensitivity or anaphylaxis), and those with anaphylaxis were discontinued. Subjects referred to the Adjudication Committee for potential hypersensitivity were allowed to continue if (i) there was no hypotension, (ii) all symptoms of hypersensitivity were rated as mild or moderate, and (iii) a blinded independent external expert with expertise in treatment of hypersensitivity review of the case recommended that it was safe for the subject to proceed to further dosing periods.
Adverse events were recorded throughout the study. Other safety assessments included physical examination, vital signs, ECG, oxygen saturation, PEF, and laboratory assessments.
The primary endpoint was the proportion of subjects with confirmed hypersensitivity symptoms for each sugammadex and placebo dose. The key secondary endpoint was the proportion of subjects with confirmed anaphylaxis.
Anti-sugammadex antibodies
The presence of anti-sugammadex antibodies was measured as an exploratory endpoint in blood samples obtained in all subjects with potential hypersensitivity and in a subset of control subjects who had received sugammadex, but did not have any hypersensitivity findings, using a three-step tiered anti-drug assay and IgG/IgE isotyping assay. An electrochemiluminescence-based screening assay was used to detect anti-sugammadex antibodies (detection limit: 0.28 ng ml À1 ). A confirmatory assay was performed, with positive samples consequently subjected to an IgG/IgE isotyping assay to detect sugammadex-specific IgG or IgE (detection limit: 143 ng ml À1 for IgG; not determined for IgE).
Tryptase
Tryptase is a mast-cell constituent, and elevations of tryptase concentrations are an indication of mast-cell degranulation. 19 Tryptase was measured as a pre-specified exploratory endpoint, with samples collected pre-dose and at 3 h post-dose for all subjects. Tryptase concentrations in subjects with anaphylaxis peak at 15e120 min and with a half-life of 1.5e2.5 h. 19 A tryptase analysis was performed using Immuno-CAP™ (Phadia, Uppsala, Sweden). The assay had a detection limit of 1.0 ng ml À1 (upper 95th percentile for basal concentrations of serum tryptase in healthy subjects is 11.4 ng ml
À1
). Measurements of tryptase concentrations were performed in subjects with potential hypersensitivity; the proportions of subjects with post-dose tryptase concentrations >11 ng ml À1 and of those with an increase of !3 ng ml À1 from the pre-dose value were assessed.
Statistical analyses
It was estimated that a total of 150 subjects in each of the sugammadex 4 and 16 mg kg À1 groups and 75 subjects in the placebo group would allow estimation of confirmed hypersensitivity amongst subjects receiving sugammadex with a 95% confidence interval (CI) with a half-width between 1.2 and 4.2 percentage points, depending upon the observed incidence. This was based on the assumptions that there would be 150 evaluable subjects for each sugammadex dose group, and of an underlying event rate of up to 6% in the sugammadex highdose group, based on the results from the prior study P06042. Hypersensitivity analyses were performed by estimating the incidence and 95% CI (ClopperePearson) 22 of confirmed hypersensitivity in each treatment group, and estimating the difference in incidence and 95% CI (Miettinen and Nurminen method) 23 between each sugammadex dose group and placebo. All safety analyses were performed using the allsubjects-as-treated population, which consisted of all Mast-cell tryptase elevation > upper normal limit randomised subjects who received at least one dose of study treatment. Subjects were included in the group corresponding to the treatment they actually received.
Results
The study was conducted from January to July 2014. In total, 382 subjects were randomised, 375 received treatment (sugammadex 4 mg kg À1 : n¼151; 16 mg kg
À1
: n¼148; and placebo: n¼76) and 334 (89.1%) completed the study and received all three doses of the assigned treatment ( Supplementary  Fig. S1 ). The overall mean (range) age was 38 (19e56) yr, BMI was 26.3 (18.7e32.0) kg m À2 , and 53% of the subjects were female. The patient and baseline characteristics were similar between the treatment groups ( Table 2 ).
Hypersensitivity
Overall, 94 subjects with a total of 137 adverse events potentially consistent with hypersensitivity based on the targeted hypersensitivity assessments were referred to the Clinical Adjudication Committee. Of these, 25 subjects were identified with adjudicated hypersensitivity after receiving at least one dose of study medication: 10 (6.6%; 95% CI: 3.2e11.8) and 14 (9.5%; 95% CI: 5.3e15.4) subjects receiving sugammadex 4 and 16 mg kg À1 , respectively, and one (1.3%; 95% CI: 0.0e7.1) randomised to placebo (Table 3 ). In 13 subjects, the onset of the first hypersensitivity symptoms occurred within 10 min after the dose administration. All subjects but one had symptoms that began within 1 h of the dose administration. One subject had delayed mild hypersensitivity symptoms 22 h post-dose. In total, 43 adjudicated hypersensitivity events were experienced by these 25 subjects. The incidence of confirmed hypersensitivity was similar across sugammadex dose groups and dosing occasions (Figs 1 and 2) . A summary of adverse events experienced by those with confirmed hypersensitivity is shown in Table 4 .
Overall, 39/43 (91%) hypersensitivity events were of mild severity; three were moderate and one was considered severe (these four events occurred in the 16 mg kg À1 group) (Fig. 1 ).
There was no clear evidence of an increase in the incidence or severity of hypersensitivity with repeated administration of sugammadex. In the 24 sugammadex subjects with hypersensitivity, 21 received all three doses: 11 subjects had an event on more than one occasion, with three in the 4 mg kg (Fig. 1) . The remaining 3 of 24 subjects (all from the 16 mg kg À1 group) required treatment for hypersensitivity symptoms and were discontinued from the study, per the prespecified protocol requirements, after the first dose. The symptoms of all three subjects rapidly improved after treatment with antihistamines/corticosteroids, and resolved completely within 22 h after symptom onset. No subject required treatment with epinephrine. Anaphylaxis was confirmed in one of these three subjects (Table 3 ; Fig. 1 ). This subject had an onset of initial symptoms immediately after the dose administration: mild sneezing, nasal congestion, conjunctival oedema, moderate urticaria, and swelling of the uvula, and a decrease in PEF 30% below baseline. Most symptoms resolved within 3 h of treatment with antihistamine and corticosteroid, with conjunctival oedema resolving 9 h after the dose administration; the subject recovered completely without sequelae. The subject did not experience hypotension.
À1
There was a numerically higher incidence of adverse events in the sugammadex 4 events in the setting of overdose were considered unrelated to the study drug by the investigator. Further details are provided in Supplementary materials. No clinically relevant changes were observed in any of the vital signs, PEF, oxygen saturation by pulse oximetry, laboratory, ECG, or other routine safety parameters in the sugammadex groups relative to the placebo group.
Anti-sugammadex antibodies
Of the 25 subjects with confirmed hypersensitivity, two were positive for anti-sugammadex IgG. One subject with adjudicated hypersensitivity on each dosing occasion had positive IgG at baseline (before receiving sugammadex), but was negative before the second and third doses, and at the follow-up visit. The second subject was negative at baseline, but positive before the second and third doses, and at the follow-up visit; this subject had an adjudicated hypersensitivity event after the second dose, but not the third. None of the subjects with adjudicated hypersensitivity were positive for anti-sugammadex IgE.
Of the 69 subjects who were referred to the Clinical Adjudication Committee but whose events were not confirmed as hypersensitivity reactions, none had anti-sugammadex IgG or IgE at any evaluated time point. Furthermore, of the 91 control subjects (who were not referred to the Clinical Adjudication Committee), none had anti-sugammadex IgG or IgE at any evaluated time point.
Overall, these findings suggest a low likelihood of developing IgE or IgG antibodies to sugammadex with repeated administration, and that antibodies to sugammadex are not associated with confirmed hypersensitivity.
Tryptase
The upper limit of the normal range of tryptase in healthy subjects is 11.4 ng ml
À1
. There were no subjects with adjudicated hypersensitivity with tryptase concentrations >11 ng ml À1 , either pre-or post-dose. One subject had a !3 ng ml À1 tryptase increase post-dose relative to pre-dose with the second dose of sugammadex. This subject also had adjudicated hypersensitivity reactions after the first and third doses, but did not have elevations of tryptase in those periods of tryptase !3 ng ml
.
Discussion
After repeated administration in healthy volunteers, sugammadex was associated with a numerically higher incidence of hypersensitivity than placebo at both 4 and 16 mg kg À1 ; the incidence of hypersensitivity was similar across sugammadex doses and dosing occasions. Most hypersensitivity events occurred within minutes after the sugammadex administration. In three events occurring in the 148 subjects in the sugammadex 16 mg kg À1 group, treatment was required with antihistamines and corticosteroids. There was no pattern of an increase in the severity of hypersensitivity reactions in the subjects who experienced hypersensitivity on more than one occasion. Thus, there was no evidence for the development of sensitisation to sugammadex in this study. Overall, there were no cases of anaphylaxis in the 151 subjects who received sugammadex 4 mg kg À1 , the highest recommended dose for routine reversal in clinical practice. There was one case of anaphylaxis in the 148 subjects receiving sugammadex 16 mg kg
À1
, which required treatment with antihistamines and corticosteroids. In a surgical setting, the dose of 16 mg kg À1 is recommended only in emergency situations, when urgent reversal of neuromuscular block is required to restore spontaneous respiration and an airway cannot be established. It is unclear, however, whether the incidence of anaphylaxis is dose related, and thus, the observed incidence of anaphylaxis in this study with the administration of sugammadex to conscious, nonanaesthetised healthy subjects is 1 in 199, or 3.3%. In contrast to the results of this study, no confirmed cases of anaphylaxis were observed in 3230 exposures to sugammadex during the Phases 2 and 3 sugammadex clinical development programme, which consisted almost entirely of sugammadex 2 or 4 mg kg À1 doses, administered in surgical patients. There were nine sugammadex-treated patients (0.3%) with confirmed hypersensitivity in this clinical trial database. There have been a number of published reports of suspected hypersensitivity after sugammadex administration Patterns of confirmed hypersensitivity by treatment group. O¼dose administered; X¼confirmed hypersensitivity at a certain dosing occasion. n¼number of subjects receiving dose; m¼number of subjects with confirmed hypersensitivity. Three subjects had a hypersensitivity event on the first dosing occasion and were withdrawn.
in surgical patients, 10À16,20 although the incidence appears to be lower than that observed in this study of conscious, nonanaesthetised subjects. This may be due in part to increased detection rates of hypersensitivity signs and symptoms in awake vs anaesthetised subjects. Additionally, the intensive targeted hypersensitivity assessment used in the protocol of the current study is also likely to result in increased finding and reporting of relevant symptoms. The mast-cell tryptase assay is considered a valuable test to detect the degranulation of mast cells with anaphylaxis. 21 In the present study, there was limited evidence of mast-cell degranulation based on the exploratory tryptase biomarker assays, with one subject having a slight increase in tryptase from baseline, but within the upper limit of the normal range, which may be expected given the mildness of the observed hypersensitivity reactions, with none of the subjects experiencing haemodynamic compromise. Furthermore, no anti-sugammadex IgE antibodies were detected in subjects with adjudicated hypersensitivity, suggesting that repeated exposure to sugammadex may not lead to the development of anti-sugammadex IgE antibodies that could result in IgE-mediated mast-cell degranulation. There was no consistent evidence that subjects exposed to sugammadex develop anti-sugammadex IgG antibodies in this study. Therefore, based on an evaluation of serum tryptase concentrations and assays for anti-sugammadex antibodies, it is unlikely that hypersensitivity to sugammadex observed in this study is mediated through sugammadexspecific IgG-or IgE-mediated stimulation of mast cells. Patient characteristics, such as race and ethnicity, may play a role in predisposition to hypersensitivity reactions.
19 Table 4 Summary of adverse events up to 24 h after dosing in subjects with confirmed hypersensitivity (n¼25). Subjects could have more than one adverse event in each category n (%) Sugammadex 4 mg kg Subject characteristics were balanced across groups. No subgroup analyses were conducted to assess the impact of race or ethnicity on potential hypersensitivity to sugammadex, as the low incidence of hypersensitivity cases in this study limited the utility of the investigation of subgroups. Another study limitation is that the anti-sugammadex antibody results rely on an in vitro assay, and because of lack of any reference antibody for IgE, the sensitivity of the assay for IgE antibodies could not be quantified. Finally, skin testing was not conducted as part of this study, as the previous study of hypersensitivity of sugammadex with repeated dosing in healthy subjects indicated that skin testing of subjects with hypersensitivity was generally negative. Based on this evaluation in healthy subjects, the present study indicates that hypersensitivity, including anaphylaxis, can occur after the administration of sugammadex in subjects who have not previously been exposed to sugammadex. The reporting of anaphylaxis in post-marketing and in the broader clinical programme of surgical patients indicates that the incidence in the surgical population may be lower than was observed in this study of non-anaesthetised healthy subjects. Regardless of this potential discrepancy, clinicians should be aware of the possibility of hypersensitivity with the administration of sugammadex. Sugammadex should not be administered to patients with known hypersensitivity to sugammadex. Practitioners should observe patients for potential hypersensitivity reactions for an appropriate period of time after the administration.
